Novo Nordisk (NVO) recently announced plans to make a significant investment of $4.1 billion (approximately DKK 27 billion) to construct a second fill and finishing manufacturing facility in Clayton, NC. This new facility aims to enhance the company's capacity to produce injectable treatments for patients with obesity and other chronic diseases. This expansion underscores NVO's commitment to addressing the growing global demand for its medical products. The investment represents one of the largest manufactu ...